**UPDATE**
The U.S. government ‘cartel’ paid large pharmacy chains like Walgreens and CVS billions of dollars to promote COVID-19 vaccines and not fill prescriptions for ivermectin.
https://brieflands.com/articles/jjhs-146703
Ivermectin as a Potential Addition to the Limited Anti-COVID-19 Arsenal: A Double-Blinded Clinical Trial
1 , Fatemeh Amini2 , Ramin Jamshididan1 , Mehrdad Dargahi3 , Nematollah Gheibi3 , Sara Abolghasemi3 , Mohammadreza Dayer4 , Negar Varnasseri3 , Khojasteh Hoseinynejad5 , * , Sahar Kheradhoosh3 , Pedram Nazari6 , ** , Ebrahim Babadi7 , Seyedeh Maryam Mousavinezhad6 , Pouya Ebrahimi8Abstract
Background:
Addressing the Coronavirus disease 2019 (COVID-19) pandemic remains a significant challenge for healthcare systems globally. Despite the absence of a proven cure, ivermectin has been proposed as a potentially effective agent against it.
Objectives:
This study aimed to evaluate the therapeutic effects of ivermectin compared to a placebo group in non-critically ill confirmed COVID-19 patients.
Methods:
A double-blind, randomized clinical trial was conducted on 110 patients with moderate-to-severe (non-critical) confirmed COVID-19 infection. The patients were equally divided into two groups, with one group receiving ivermectin tablets (14 mg every 12 hours for three days) and the other group receiving a placebo. The efficacy and safety of ivermectin were assessed in both groups.
Results:
A total of 110 patients, including 62 (56.4%) men and 48 (43.6%) women, with an average age of 53.36 ± 15.10 years, were enrolled in our double-blind, randomized clinical trial. The baseline characteristics of the two groups were similar. The findings demonstrated that ivermectin significantly reduced the need for Intensive Care Unit admission (32.7% vs. 5.5%; P < 0.001), hospitalization duration (six vs. four days; P < 0.001), and median time to symptom resolution period (P < 0.05) in COVID-19 patients compared to the placebo group, without any serious side effects (P > 0.05).
Conclusions:
Ivermectin appears to be a potentially effective and safe medication for COVID-19 patients with moderate disease.
- https://madisonarealymesupportgroup.com/2021/04/05/censored-dr-peter-mccullough-testifies-how-successful-home-treatments-for-covid-make-experimental-vaccines-unnecessary-home-treatment-protocol-by-aaps-included/
- https://madisonarealymesupportgroup.com/2021/01/05/fareed-tyson-covid-19-treatment-protocol/
- https://madisonarealymesupportgroup.com/2021/04/27/covid-natural-remedies-banned-as-doj-ftc-seek-to-silence-doctors-promoting-vitamin-d-c-zinc-etc/ Scroll to comment section for a list of treatments
- https://madisonarealymesupportgroup.com/2020/07/10/food-as-medicine-a-possible-preventive-measure-against-covid-19/
- https://madisonarealymesupportgroup.com/2020/04/07/covid-19-integrative-support-in-prevention-early-interventions/
- https://madisonarealymesupportgroup.com/2020/06/15/the-functional-medicine-approach-to-covid-19-virus-specific-nutraceutical-botanical-agents/
- MATH+ Protocol: https://covid19criticalcare.com/covid-19-protocols/math-plus-protocol/
- Vitamin D: https://www.mdpi.com/2072-6643/12/11/3361/htm
- Vitamins D, C, Quercetin, Zinc, Melatonin, as well as Ivermectin: https://covid19criticalcare.com/covid-19-protocols/i-mask-plus-protocol/
- HCQ (often used in conjunction with zinc and Azithromycin): https://techstartups.com/2020/04/21/dr-vladimir-zelenko-now-treated-1450-coronavirus-patients-2-deaths-using-hydroxychloroquine-99-99-success-rate-latest-video-interview/, https://madisonarealymesupportgroup.com/2020/08/08/new-report-turkeys-use-of-hcq-early-saves-lives-fauci-should-be-in-jail/, https://madisonarealymesupportgroup.com/2020/06/16/aaps-sues-fda-for-irrational-interference-of-access-to-life-saving-hydroxychloroquine/
Madison Area Lyme Support Group 